Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides

Many tyrosine kinase-driven cancers, including chronic myeloid leukemia (CML), are characterized by high response rates to specific tyrosine kinase inhibitors (TKIs) like imatinib. In East Asians, primary imatinib resistance is caused by a deletion polymorphism in Intron 2 of the BIM gene, whose pro...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Liu, Jun, Bhadra, Malini, Sinnakannu, Joanna Rajeswary, Yue, Wan Lin, Tan, Cheryl Weiqi, Rigo, Frank, Ong, S.Tiong, Roca, Xavier
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2017
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5652800/
https://ncbi.nlm.nih.gov/pubmed/29100409
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20658
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia